PATENT CLAIM ANALYSIS

Application Number: 16295536
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["424", "133100"]

Abstract:
Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

Claim (Index 1):
A method of treating a patient having a gastrointestinal inflammatory disorder, the method comprising: (a) measuring the mRNA expression level of TNFSF15 in a biological sample from the patient; (b) comparing the mRNA expression level of TNFSF15 measured in (a) to a reference level for TNFSF15; (c) identifying the patient as likely to have a response to a therapy comprising an integrin beta7 antagonist based on the detection of a lower level of mRNA expression of TNFSF15 in the biological sample as compared to the reference level for TNFSF15; and (d) administering to the patient the therapy.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 99.0
- Lexical Diversity: 1.84615
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15271687', '14675081', '13348709', '12390730', '11219121']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6934666354780117
- 35 USC 102 Novelty (BERT): 0.7524132475221478
- Combined Prediction Score: 0.6993612966824253
- Mean Citation Score: 470.705118
- Max Citation Score: 938.87976
- Similarity Product: 838.0517404249191

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test